Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells

Kotmakçı, Mustafa; Çetintaş, Vildan Bozok; Kantarcı, Ayşe Gülten

doi:10.1016/j.ijpharm.2017.04.034

Cited by 28 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLN-STAT3 decoy ODN complexes increased expression of cleaved caspase 3, Bax, Beclin-1 and LC3-II and reduced expression of Bcl-2, pro-caspase 3, Survivin, p-Akt, and pmTOR in human ovarian cancer cell lines (181). Overexpression of STAT3 in Non-Small Cell Lung Cancer (NSCLC) patients is a strong predictor of poor prognosis, cationic solid lipid nanoparticles (cSLN) were used to deliver RNAi-mediating plasmid DNA targeting STAT3 in cisplatin resistant lung cancer cells (182, 183). STAT3 mRNA expression level were lowered by ~5-fold in chemo-resistant Calu1 NSCLC cells after treatment of cSLN:plasmid DNA complexes (K2 and K3) (182).…”

Section: Other Strategies In Targeting Stat3/5mentioning

confidence: 99%

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

et al. 2019

View full text Add to dashboard Cite

Signal Transducer and Activator of Transcription (STAT) pathway is connected upstream with Janus kinases (JAK) family protein and capable of integrating inputs from different signaling pathways. Each family member plays unique functions in signal transduction and crucial in mediating cellular responses to different kind of cytokines. STAT family members notably STAT3 and STAT5 have been involved in cancer progression whereas STAT1 plays opposite role by suppressing tumor growth. Persistent STAT3/5 activation is known to promote chronic inflammation, which increases susceptibility of healthy cells to carcinogenesis. Here, we review the role of STATs in cancers and inflammation while discussing current therapeutic implications in different cancers and test models, especially the delivery of STAT3/5 targeting siRNA using nanoparticulate delivery system.

show abstract

Section: Other Strategies In Targeting Stat3/5mentioning

confidence: 99%

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Compared with matched primary tumors, the STAT3 phosphorylation level is increased in drug‐resistant recurrent tumors [ 29 , 30 ]. Inactivation of STAT3 can overcome drug resistance in lung cancer [ 31 , 32 ]. In osteosarcoma cells, inhibition of STAT3 increases the sensitivity of chemotherapy‐resistant cells and eliminates drug efflux [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway

Cong

Liu

et al. 2021

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

“…Encapsulation of DNA by SLNs preserved its supercoiled and circular formation. STAT3 inhibitor-loaded SLNs significantly sensitized lung cancer cells to cisplatin-mediated apoptosis (Table 3) [186]. In respect to the potential role of STAT3 in enhancing the malignancy of cancer cells [187], this signaling pathway has obtained much attention in triple negative breast cancer (TNBC) therapy and a number of drugs approved by the Food and Drug Administration (FDA) such as niclosamide have been used in treatment of TNBC as inhibitors of STAT3 [188].…”

Section: Nano-technological Approaches For Targeting Statsmentioning

confidence: 99%

Nanoparticles Targeting STATs in Cancer Therapy

Ashrafizadeh

Ahmadi

Kotla

et al. 2019

Cells

View full text Add to dashboard Cite

Over the past decades, an increase in the incidence rate of cancer has been witnessed. Although many efforts have been made to manage and treat this life threatening condition, it is still one of the leading causes of death worldwide. Therefore, scientists have attempted to target molecular signaling pathways involved in cancer initiation and metastasis. It has been shown that signal transducers and activator of transcription (STAT) contributes to the progression of cancer cells. This important signaling pathway is associated with a number of biological processes including cell cycle, differentiation, proliferation and apoptosis. It appears that dysregulation of the STAT signaling pathway promotes the migration, viability and malignancy of various tumor cells. Hence, there have been many attempts to target the STAT signaling pathway. However, it seems that currently applied therapeutics may not be able to effectively modulate the STAT signaling pathway and suffer from a variety of drawbacks such as low bioavailability and lack of specific tumor targeting. In the present review, we demonstrate how nanocarriers can be successfully applied for encapsulation of STAT modulators in cancer therapy.

show abstract

Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells

Cited by 28 publications

References 27 publications

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway

Nanoparticles Targeting STATs in Cancer Therapy

Contact Info

Product

Resources

About